<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660348</url>
  </required_header>
  <id_info>
    <org_study_id>JHOC-J0724 CDR0000593173</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0724</secondary_id>
    <secondary_id>JHOC_NA_00009208</secondary_id>
    <nct_id>NCT00660348</nct_id>
  </id_info>
  <brief_title>Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Randomized Study of Optimal Pain Management: Standard Pain Control Versus Early Intervention With Intrathecal Therapy in Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving medications in different ways may change their effectiveness in controlling
      pain. It is not yet known whether intrathecal therapy is more effective than standard therapy
      in controlling pain in patients with pancreatic cancer.

      PURPOSE: This randomized clinical trial is studying standard pain control to see how well it
      works compared with intrathecal therapy in controlling pain in patients with locally
      advanced, unresectable, or metastatic pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the effectiveness of pain control comprising intrathecal opioid delivery
           versus the standard analgesia-delivery method in patients with locally advanced,
           unresectable, or metastatic pancreatic cancer.

      Secondary

        -  To assess the difference of a total amount of opioid consumption (parenteral morphine
           equivalent) between two different opioids-delivery groups at one month of treatment.

        -  To assess the average of percent change in Karnofsky performance status with respect to
           the baseline status between two different analgesic-delivery groups at one month of
           treatment.

        -  To assess the difference in quality of life between two different opioids-delivery
           groups at one month of treatment using the EORTC QLQ-C30.

        -  To assess overall survival of these patients.

        -  To assess the safety profile of two different analgesic-delivery methods (i.e., adverse
           event and serious adverse event).

      OUTLINE: Patients are stratified according to Karnofsky performance status (60-80% vs &gt; 80%).
      Patients are randomized to 1 of 2 treatment arms.

        -  Arm I (standard pain management): Patients are evaluated by the JHH Pain Medicine
           Integrated Team for pain, for the potential of diagnostic/neurolytic celiac plexus
           block, and undergo the institution of or modification of or continuation and titration
           of oral or parenteral analgesics. Patients undergo a limited, problem-oriented physical
           exam including weight, vital signs, Karnofsky performance status (KPS), assessment of
           previously abnormal findings or new complaints, pain scores, analgesia consumption, side
           effects (i.e., sleepiness, nausea, pruritus, and constipation), and quality-of-life
           score (EORTC QLQ-C30) once every 2 weeks for 3 months and then once a month thereafter.
           Patients also keep a diary of pain scores and side effects during the trial. Patients
           may have their treatment titrated as needed to control their pain. Patients who are not
           adequately pain controlled or develop debilitating side effects from their therapy may
           be managed by adjuvant analgesics or be allowed to crossover into the treatment arm of
           the study to provide compassionate care.

        -  Arm II (intrathecal therapy): Patients undergo implantation of a Medtronic intrathecal
           pump and catheter system for delivery of morphine sulfate directly into the spinal
           fluid. Following implantation, patients undergo a limited, problem-oriented physical
           exam including vital signs, KPS, assessment of previously abnormal findings or new
           complaints, pain scores, analgesia consumption, and quality-of life-score (EORTC
           QLQ-C30) once every 2 weeks for 3 months and then once a month thereafter. Patients are
           also evaluated by the Interventional Pain Treatment Team for wound status, presence of
           symptoms of post-dural puncture headache, signs of infection, or meningitis. Patients
           are followed by the JHH Pain Medicine Integrated Team for evaluation of pain and for
           institution of or modification of or continuation and titration of oral or parenteral
           analgesics.

      After completion of study treatment, patients are followed for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Per Arm With Decrease in Pain Scores</measure>
    <time_frame>1 month</time_frame>
    <description>The primary objective of this study is to compare the effectiveness of pain control between intrathecal opioid delivery and standard analgesia delivery method in patients with locally advanced unresectable or metastatic pancreatic cancer. The primary end point is the number of subjects on each arm showing a decrease in the change in VAS self-assessment pain intensity rating (VAS pain rating) at one month from initial treatment with respect to the baseline pain score. The change is defined as (the Pain Score at one month of the treatment - the Pain Score at baseline). Serial pain scores will be collected at all assessment time points. Min: zero cm. Max 10cm. A higher value means worse pain. Subjects on each arm will report pain on a 10 cm Visual Analogue Scale (VAS) pain rating scale, by making a mark on the 10cm horizontal line with a pen and study team will measure distance from the mark to the start of the scale, which will indicate pain score (eg 1 cm, 3 cm 6 cm, etc.).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Pain</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>morphine given traditionally (IV, pill, patch). This is standard of care dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal pump</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine sulfate</intervention_name>
    <description>This is morphine given in the traditional methods.</description>
    <arm_group_label>morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic intrathecal pump</intervention_name>
    <description>This pump will be inserted into the research subject and then the pump will deliver morphine.</description>
    <arm_group_label>Intrathecal pump</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically confirmed adenocarcinoma of the pancreas

               -  Mixed adenocarcinoma tumors allowed provided the predominant invasive component
                  of the tumor is adenocarcinoma

          -  Locally advanced, unresectable, or metastatic disease

          -  Patients must be within two months of diagnosis or have started chemotherapy within 60
             days of study

          -  Average pain score â‰¥ 4/10 over a 7-day period on a verbal numerical rating scale

        Exclusion criteria:

          -  Known brain metastases

          -  Tumor with clinically significant obstruction of the spinal canal

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Karnofsky performance status 60-100%

          -  ANC â‰¥ 1,500 cells/mmÂ³

          -  Hematocrit â‰¥ 28%

          -  WBC â‰¥ 3,500 cells/mmÂ³

          -  Platelets â‰¥ 90,000/mmÂ³

          -  Serum creatinine â‰¤ 2.0 mg/dL

          -  Bilirubin â‰¤ 2.5 mg/dL

          -  AST/ALT â‰¤ 5 times upper limit of normal (ULN)

          -  Alkaline phosphatase â‰¤ 5 times ULN

          -  INR â‰¤ 1.5

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Mini-mental status exam score â‰¥ 22

        Exclusion criteria:

          -  Uncontrolled medical conditions that could potentially increase the risk of toxicities
             or complications of this therapy, including any of the following:

               -  Gastrointestinal tract disease resulting in an inability to take oral medication
                  or a requirement for IV alimentation

               -  Active peptic ulcer disease

          -  Active infections

          -  Insensitive to opioid medication for cancer pain

          -  Insufficient tissue or decubitus ulcer near device implantation site

          -  Current history of substance abuse

        PRIOR CONCURRENT THERAPY:

          -  Minor procedures (i.e., dental work or skin biopsy), tumor biopsies, and biliary stent
             placement are allowed

          -  No prior surgical procedures affecting absorption

          -  Prior or other concurrent pain medications are allowed

          -  Concurrent chemotherapy or radiotherapy allowed at the discretion of the treating
             physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Erdek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <results_first_submitted>May 21, 2014</results_first_submitted>
  <results_first_submitted_qc>October 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 8, 2014</results_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>pain</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Morphine</title>
          <description>morphine given traditionally (IV, pill, patch)
morphine sulfate: This is morphine given in the traditional methods.</description>
        </group>
        <group group_id="P2">
          <title>Intrathecal Pump</title>
          <description>Pump internal used to deliver morphine. This is a newer method for delivery of morphine.
Medtronic intrathecal pump: This pump will be inserted into the research subject and then the pump will deliver morphine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Morphine</title>
          <description>morphine given traditionally (IV, pill, patch)
morphine sulfate: This is morphine given in the traditional methods.</description>
        </group>
        <group group_id="B2">
          <title>Intrathecal Pump</title>
          <description>Pump internal used to deliver morphine. This is a newer method for delivery of morphine.
Medtronic intrathecal pump: This pump will be inserted into the research subject and then the pump will deliver morphine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="55" upper_limit="55"/>
                    <measurement group_id="B3" value="55" lower_limit="55" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Per Arm With Decrease in Pain Scores</title>
        <description>The primary objective of this study is to compare the effectiveness of pain control between intrathecal opioid delivery and standard analgesia delivery method in patients with locally advanced unresectable or metastatic pancreatic cancer. The primary end point is the number of subjects on each arm showing a decrease in the change in VAS self-assessment pain intensity rating (VAS pain rating) at one month from initial treatment with respect to the baseline pain score. The change is defined as (the Pain Score at one month of the treatment - the Pain Score at baseline). Serial pain scores will be collected at all assessment time points. Min: zero cm. Max 10cm. A higher value means worse pain. Subjects on each arm will report pain on a 10 cm Visual Analogue Scale (VAS) pain rating scale, by making a mark on the 10cm horizontal line with a pen and study team will measure distance from the mark to the start of the scale, which will indicate pain score (eg 1 cm, 3 cm 6 cm, etc.).</description>
        <time_frame>1 month</time_frame>
        <population>One subject was enrolled, and baseline pain score was obtained on questionnaire, but the subject came off-study before follow-up pain score could be collected. Study terminated shortly thereafter. No outcome data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Morphine</title>
            <description>morphine given traditionally (IV, pill, patch). This is standard of care dosing.
morphine sulfate: This is morphine given in the traditional methods.</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Pump</title>
            <description>Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20
Medtronic intrathecal pump: This pump will be inserted into the research subject and then the pump will deliver morphine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Per Arm With Decrease in Pain Scores</title>
          <description>The primary objective of this study is to compare the effectiveness of pain control between intrathecal opioid delivery and standard analgesia delivery method in patients with locally advanced unresectable or metastatic pancreatic cancer. The primary end point is the number of subjects on each arm showing a decrease in the change in VAS self-assessment pain intensity rating (VAS pain rating) at one month from initial treatment with respect to the baseline pain score. The change is defined as (the Pain Score at one month of the treatment - the Pain Score at baseline). Serial pain scores will be collected at all assessment time points. Min: zero cm. Max 10cm. A higher value means worse pain. Subjects on each arm will report pain on a 10 cm Visual Analogue Scale (VAS) pain rating scale, by making a mark on the 10cm horizontal line with a pen and study team will measure distance from the mark to the start of the scale, which will indicate pain score (eg 1 cm, 3 cm 6 cm, etc.).</description>
          <population>One subject was enrolled, and baseline pain score was obtained on questionnaire, but the subject came off-study before follow-up pain score could be collected. Study terminated shortly thereafter. No outcome data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Morphine</title>
          <description>morphine given traditionally (IV, pill, patch)
morphine sulfate: This is morphine given in the traditional methods.</description>
        </group>
        <group group_id="E2">
          <title>Intrathecal Pump</title>
          <description>Pump internal used to deliver morphine. This is a newer method for delivery of morphine.
Medtronic intrathecal pump: This pump will be inserted into the research subject and then the pump will deliver morphine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>epigastric pain (upper quadrant)</sub_title>
                <description>grade 3 epigastric pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>reflux intermittent</sub_title>
                <description>grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <description>grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Subject started study 7/14/2010, but withdrew her consent on 7/24/2010 due to increased upper quadrant pain. One subject enrolled. She withdrew consent before study team could collect any follow-up data. We do not have any participants to analyze.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Erdek, MD</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center</organization>
      <phone>410-502-7388</phone>
      <email>merdek1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

